OCT Biomarkers for Diabetic Retinopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02330042|
Recruitment Status : Active, not recruiting
First Posted : January 1, 2015
Last Update Posted : July 14, 2021
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||165 participants|
|Official Title:||Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
Group C (controls)
Patients without diabetes or evidence of any form of eye disease
- Number of participants with decreased total retinal blood flow by OCT angiography [ Time Frame: 1 year ]Total retinal blood flow will be measured in uL/min.
- Number of participants with capillary dropout and/or new abnormal retinal blood vessel growth by OCT angiography [ Time Frame: 1 year ]Neovascular membrane area will be measured in mm2.
- Number of participants with measureable macular edema by OCT imaging [ Time Frame: 1 year ]Retinal thickening area will be measured in mm2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02330042
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Thomas Hwang, MD||Oregon Health and Science University|